TY - JOUR
T1 - The clinical impacts of pretreatment peripheral blood ratio on lymphocytes, monocytes, and neutrophils among patients with laryngeal/ hypopharyngeal cancer treated by chemoradiation/radiation
AU - Chuang, Hui Ching
AU - Tsai, Ming Hsien
AU - Lin, Yu Tsai
AU - Chou, Ming Huei
AU - Huang, Tai Lin
AU - Chiu, Tai Jan
AU - Lu, Hui
AU - Fang, Fu Min
AU - Chien, Chih Yen
N1 - Publisher Copyright:
© 2020 Chuang et al.
PY - 2020
Y1 - 2020
N2 - Purpose: This study aimed to investigate the clinical impacts of the pretreatment peripheral blood ratios of lymphocytes, monocytes and neutrophils among patients with hypopharyn-geal cancer/laryngeal cancer. Patients and Methods: A total of 141 people with cases of hypopharyngeal cancer/ laryngeal cancer were enrolled to evaluate the clinical impacts of the systemic inflammation response index (SIRI), neutrophil–lymphocyte ratio (NLR) and lymphocyte–monocyte ratio (LMR) in pretreatment blood among patients with laryngeal/hypopharyngeal cancer between January 2012 and December 2014. Results: Those patients with higher pretreatment LMR (>2.99) showed a significantly higher 5-year complete response rate (CR) (69% vs 31%) than those with lower LMR (≤2.99, p = 0.006). Additionally, those patients with lower pretreatment SIRI (<3.26) showed a significantly higher 5-year CR (90% vs 10%) than those with higher SIRI (≥3.26, p < 0.001). Patients with higher LMR had better 5-year overall survival (OS) (p = 0.01) and 5-year progression-free (PFS) (p = 0.005) rates than those with lower LMR in univariate analysis. Patients with lower SIRI had better 5-year OS (p < 0.001) and 5-year PFS (p < 0.001) than those with higher SIRI in univariate analysis. In the Cox regression analysis, SIRI (HR = 1.941, [95% CI: 1.223–3.081], p = 0.005) and N classification (HR = 2.203, [95% CI: 1.327–3.657], p = 0.002) were independent variables of 5-year OS. In addition, SIRI (HR= 2.127, [95% CI: 1.214–3.725], p = 0.008), T classification (HR = 2.18, [95% CI: 1.072–4.433], p = 0.031), and N classification (HR = 2.329, [95% CI: 1.395–3.889], p = 0.001) were independent variables of 5-year PFS. Conclusion: Pretreatment SIRI is superior to LMR in predicting treatment response and clinical outcomes among patients with laryngeal/hypopharyngeal cancer treated by CRT/RTO. SIRI may be adopted in the treatment of laryngeal/hypopharyngeal cancer by CRT/RTO.
AB - Purpose: This study aimed to investigate the clinical impacts of the pretreatment peripheral blood ratios of lymphocytes, monocytes and neutrophils among patients with hypopharyn-geal cancer/laryngeal cancer. Patients and Methods: A total of 141 people with cases of hypopharyngeal cancer/ laryngeal cancer were enrolled to evaluate the clinical impacts of the systemic inflammation response index (SIRI), neutrophil–lymphocyte ratio (NLR) and lymphocyte–monocyte ratio (LMR) in pretreatment blood among patients with laryngeal/hypopharyngeal cancer between January 2012 and December 2014. Results: Those patients with higher pretreatment LMR (>2.99) showed a significantly higher 5-year complete response rate (CR) (69% vs 31%) than those with lower LMR (≤2.99, p = 0.006). Additionally, those patients with lower pretreatment SIRI (<3.26) showed a significantly higher 5-year CR (90% vs 10%) than those with higher SIRI (≥3.26, p < 0.001). Patients with higher LMR had better 5-year overall survival (OS) (p = 0.01) and 5-year progression-free (PFS) (p = 0.005) rates than those with lower LMR in univariate analysis. Patients with lower SIRI had better 5-year OS (p < 0.001) and 5-year PFS (p < 0.001) than those with higher SIRI in univariate analysis. In the Cox regression analysis, SIRI (HR = 1.941, [95% CI: 1.223–3.081], p = 0.005) and N classification (HR = 2.203, [95% CI: 1.327–3.657], p = 0.002) were independent variables of 5-year OS. In addition, SIRI (HR= 2.127, [95% CI: 1.214–3.725], p = 0.008), T classification (HR = 2.18, [95% CI: 1.072–4.433], p = 0.031), and N classification (HR = 2.329, [95% CI: 1.395–3.889], p = 0.001) were independent variables of 5-year PFS. Conclusion: Pretreatment SIRI is superior to LMR in predicting treatment response and clinical outcomes among patients with laryngeal/hypopharyngeal cancer treated by CRT/RTO. SIRI may be adopted in the treatment of laryngeal/hypopharyngeal cancer by CRT/RTO.
KW - Head and neck squamous cell carcinoma
KW - Hypopharyngeal cancer
KW - Laryngeal cancer
KW - Lymphocyte– monocyte ratio
KW - Neutrophil–lymphocyte ratio
KW - Systemic inflammation response index
UR - http://www.scopus.com/inward/record.url?scp=85091652033&partnerID=8YFLogxK
U2 - 10.2147/CMAR.S275635
DO - 10.2147/CMAR.S275635
M3 - 文章
AN - SCOPUS:85091652033
SN - 1179-1322
VL - 12
SP - 9013
EP - 9021
JO - Cancer Management and Research
JF - Cancer Management and Research
ER -